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Chinese mainlandCYP2E1 is one of a superfamily of enzymes that play a central role in activating and detoxifying many
xenobiotics and endogenous compounds thought to be involved in the development of several human
diseases. Among other factors, individual susceptibility to developing these pathologies relies on genetic
polymorphisms, which are related to ethnic differences, since the frequency of mutant genotypes varies in
different populations. The aim of this study was to investigate the genetic basis of CYP2E1 polymorphisms in
the populations of four different geographical locations of China. Twenty-two different CYP2E1
polymorphisms, including six novel variants in promoter regions and a novel nonsense mutation, were
identiﬁed. The frequencies of some polymorphisms and genotypes demonstrated signiﬁcant differences
among the four populations. Linkage disequilibrium analysis and tag SNP selection were performed.
Haplotypes were analyzed within the selected tag SNPs. Tag SNP selection and haplotype distributions
showed differences across the four populations.h Center, Shanghai Jiao Tong
Biomedical Sciences, Fudan
hina. Fax: +86 21 62822491.
nsir@sjtu.edu.cn (S. Qin).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The cytochrome P450 enzymes (CYP) play a central role in the
metabolism of many xenobiotics and endogenous compounds
including drugs, food additives, industrial solvents, and pollutants,
converting them to reactive metabolites [1]. Besides detoxiﬁcation,
they often catalyze the metabolic activation of procarcinogens to their
ultimate carcinogenic forms. A great part of the interindividual and
interethnic differences in the metabolism of many xenobiotics and
endogenous compounds is now attributed to genetic differences in
their metabolism. Mutations in a gene that code for an enzyme
metabolizing these substances can give rise to enzyme variants with
higher, lower, or no activity at all [2]. Thus, populations can be divided
into phenotypes of poor metabolizers (PMs), intermediate metabo-
lizers (IMs), extensive metabolizers (EMs), and ultrarapid metaboli-
zers (UMs). Individualized drug therapy based on genotype analysis
therefore promises to be an effective method of reducing adverse
effects and improving drug efﬁcacy.
Among the various P450s, CYP2E1 is of particular interest due to its
role in the metabolism and bioactivation of many low molecular
weight compounds, including ethanol, acetone, drugs such asacetaminophen, isoniazid, chlorzoxazone, and xuorinated anesthetics,
and many procarcinogens such as benzene, N-nitrosodimethylami-
nen, and styrene [3-5]. The CYP2E1 gene exhibits several genetic
polymorphisms that are thought to play a major role in interindivid-
ual variability in drug response, drug–drug, drug–xenobiotic interac-
tions and in susceptibility to chemical-induced diseases [1,6]. Of the
known polymorphisms, the CYP2E1⁎1D allele contains a repeat
sequence in the 5′-ﬂanking region of the gene that may function as
a negative regulatory element [7]. Individuals with the CYP2E1⁎1D
genotype who had recently consumed alcohol or were obese have
been found to have higher CYP2E1 activity [8]. The CYP2E1⁎1D allele
has also been associated with increased risk of esophageal and
colorectal cancers, which are diseases related to alcohol and tobacco
abuse [9,10]. The CYP2E1⁎6 polymorphism is located in intron 6 [11].
This change assumes that it is the polymorphism and not the intron
that lowers “chlorzoxazonemetabolic ratios” [12] and to be correlated
with single strand breaks in DNA [13].
Several reports have demonstrated that CYP2E1 polymorphisms
differ markedly in frequency among different ethnic and racial groups
[14]. However, there has been virtually no comprehensive search for
genetic polymorphisms of CYP2E1 gene in the Chinese Han
population.
As the largest population (nearly 20%) in the world, the Chinese
Han population is spread over the third largest populated area with a
land mass of about 9.6 million km2. In addition, the Han population is
the largest ethnic group in China and is spread widely across the
1 Arlequin: Software for population genetics data analysis, http://anthro.unige.ch/
software/arlequin.
2 Haploview, www.broad.mit.edu/mpg/haploview.
3 CONREAL: Searching transcription factor binding sites, http://conreal.niob.knaw.
nl/.
4 CYP2E1 allele nomenclature, www.cypalleles.ki.se/cyp2e1.htm.
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225K. Tang et al. / Genomics 95 (2010) 224–229country. The Han population has a very long and complex demo-
graphic history, and the population stratiﬁcation arising from the
interplay of different geographic areas will therefore have inﬂuenced
the polymorphism pattern. No polymorphism study of the CYP2E1
gene focusing on the different geographic Han populations has been
carried out to date. Moreover, speciﬁc haplotypes and allele
combinations rather than single polymorphisms may provide a better
basis for individualizing treatment. However, no systematic polymor-
phism screening, linkage disequilibrium (LD) pattern analysis, or
haplotype analysis of the whole CYP2E1 gene has been conducted in
either the Han or any other ethnic group in China.
A database of CYP2E1 allele frequencies for normal Chinese Han
subjects would be useful for optimizing pharmacotherapy with
CYP2E1-substrate drugs and we therefore aimed to systematically
screen the polymorphisms of the CYP2E1 gene in the four different
geographical groups making up the Chinese Han population namely
those in the north, south, west, and east of the Chinese mainland. We
also investigated the LD pattern and haplotype construction of this
gene in these populations. To the best of our knowledge, this is the
ﬁrst study to systematically screen the polymorphisms of the whole
CYP2E1 gene in a large Chinese Han population.
Materials and methods
Subjects
Blood samples were obtained from 400 healthy unrelated
volunteers living in four different areas of the Chinese mainland:
100 subjects from Xian City, which lies in the west of China; 100
subjects from Shanghai City, which lies in the east of China; 100
subjects from Shenyang City, which lies in the north of China; and 100
subjects from Shantou City, which lies in the south of China. Each
group of 100 subjects consisted of 50 males and 50 females between
18 and 53 years of age. All subjects were judged to be in good health in
terms of theirmedical history and after a physical examination. All the
volunteers in this study were of homogenous Chinese Han ethnicity.
The studywas approved by the Shanghai Ethical Committee of Human
Genetic Resources and all subjects gave informed consent for their
participation.
Polymerase chain reaction condition and DNA sequencing
Systematic polymorphism screening was performed by direct
sequencing. Genomic DNA was isolated from peripheral blood [15].
PCR primers were designed to amplify 2000 bp of the 5′-ﬂanking
regions and all exons of the CYP2E1 gene. The PCRs were carried out
on the Gene Amp® PCR system 9700 (Applied Biosystems, CA, USA).
The ampliﬁcation mixture contained a ﬁnal volume of 25 μl: 10 ng of
genomic DNA, 10 mM Tris–HCl (pH 8.3), 50 mM KCl, 1.5–3.0 mM
MgCl2, 200 mM dNTP, 1 mM of each primer, and 0.25 U Taq DNA
polymerase. The ampliﬁcation conditions were 95 °C for 1 min,
followed by 30–35 cycles at 95 °C for 30 s, 50–65 °C for 1min, 72 °C for
1 min, then a ﬁnal extension at 72 °C for 10 min. Preparation of DNA
for sequencing included incubation of PCR products with 0.1 U of
shrimp alkaline phosphatase (Roche, Basel, Switzerland) and 0.5 U of
exonulease I (New England Biolabs, MA, USA) at 37 °C for 45 min,
followed by heat inactivation at 85 °C for 20 min. The PCR products
were sequenced using an ABI Prism® BigDye Terminator Cycle
Sequencing Kit, version 3.1 (Applied Biosystems) on an ABI Prism
3730 sequencer.
Statistical analysis
Allele and genotype frequencies were calculated using the
counting method. X2 multiple comparison was performed to detect
differences in polymorphic frequencies among the populations fromthe four different cities. P-values were corrected according to
Bonferroni's method. Pb0.05 was considered to be statistically
signiﬁcant. The Arlequin program was used to determine whether
the CYP2E1 allelic frequencies conformed to Hardy–Weinberg
equilibrium.1 Linkage disequilibrium and haplotype block structures
were estimated by the conﬁdence-interval method using the Haplo-
view program.2
Analysis of functional sequences in the promoter region
The transcription factor binding analysis of the polymorphisms in
the promoter region was performed on the web-based software
Conserved Regulatory Element anchored Alignment (CONREAL).3
Analysis of the functional novel amino acid substitution
The signiﬁcance of Arg337Stop was predicted based on the crystal
structure model of CYP2E1 (PDB code 3E6I).
Results
A total of 22 different genetic variants were detected in the 5′-
regulatory region and all exons of the CYP2E1 gene in the 400
samples. The genotype and allele frequencies were analyzed using the
Arlequin program and were in equilibrium with the Hardy–Weinberg
equation. In the 5′-ﬂanking region, 16 variants were identiﬁed,
including 6 novel ones. The CONREAL analysis showed that all novel
polymorphisms found in the promoter region produced altered
transcription factor binding efﬁciency (Table 1). In the exons, 5
variants were detected, including one novel nonsense mutation
(C1009→T, p.337R→stop codon) in a Shantou subject in exon 7
with a frequency of 0.5%. We also carried out a statistical comparison
of all the polymorphism frequencies in the four different geographic
populations. All the polymorphisms and their allele frequencies found
in the study are summarized in Table 2 and the P-values within the
four populations are shown in Table 3.
The CYP2E1 alleles and genotypes were identiﬁed on the basis of
the polymorphisms found in the study.We found 4 CYP2E1 alleles and
7 genotypes in the mainland Chinese Han population. The CYP2E1
alleles identiﬁed were CYP2E1⁎1, ⁎2, ⁎5, and ⁎7 while ⁎3, ⁎4, and ⁎6
were not detected in the population sampled.4 The most frequent
alleles were the wild-type allele ⁎1 (49.5%) followed by ⁎7 (33.9%),
and the ⁎5 allele (16.1%). Frequencies of some alleles such as ⁎2 were
low (b1%), but this allele was detected only in the Shanghai
population. The CYP2E1 genotype frequencies are summarized in
Table 4.
To calculate the extent of linkage disequilibrium (LD) in pairwise
combinations of the SNPs, we calculated D′ and correlation of alleles
Table 2
Polymorphisms and frequencies in four different geographical Chinese Han populations.
Position⁎ Region Variant Minor allele Allele frequencies (%)
Shantou Shanghai Shenyang Xian Chinese
−1778GNA Promoter Novel A 0 0 0 0.5 0.1
−1653GNC Promoter rs3813865 C 18.7 14 23.4 22.4 19.7
−1646ANG Promoter Novel G 0 1 0.5 0.5 0.5
−1563TNA Promoter rs3813866 A 26.2 29 16.7 15.6 21.8
−1513TNG Promoter rs8192766 G 36.3 38.4 28.8 39.4 36.9
−1293GNC Promoter rs3813867 C 24.1 27.4 14.4 14.3 20
−1053CNT Promoter rs2031920 T 23.9 26.6 17.2 16 20.9
−1025TNC Promoter rs2031921 C 25 28.6 16.1 17 21.7
−971ANC Promoter Novel C 0 0 0 0.5 0.1
−962ANG Promoter Novel G 0 0 0 0.5 0.1
−929ANG Promoter rs3813870 G 18.4 14.9 18.3 21.4 18.9
−806TNC Promoter rs2031922 C 25.3 27.9 16.9 16.7 21.5
−792TNG Promoter Novel G 0 1 0 0.5 0.4
−722ANG Promoter Novel G 0 0 0 0.5 0.1
−352ANG Promoter rs2070672 G 18.8 14.1 18.8 21.9 18.4
−333TNA Promoter rs2070673 A 45.3 40.1 35.9 36.5 46.7
227GNA Exon 2 rs72559710 A 0 1 0 0 0.2
517GNA Exon 4 rs60452492 A 0 0 0 0.5 0.1
1009CNT Exon 7 Novel T 0.5 0 0 0 0.1
1263CNT Exon 8 rs2515641 T 17.7 10.4 17.2 15.1 15.1
1523TNA 3′UTR rs2480257 T 42.2 39.1 36.6 36.8 38.6
1528TNC 3′UTR rs2480256 T 42.2 39.1 36.6 36.8 38.6
⁎ The position in the gene is that indicated by the reference sequence of J02843 in the GeneBank.
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possible pairs of SNPs. The results are shown in Fig. 1. The tag
polymorphisms were selected separately in the four geographical
populations using Haploview analysis. The haplotypes were con-
structed from the tag SNPs in each population. The tag SNP selection
and haplotype frequencies for the four different geographical
populations are summarized in Table 5. The results show that each
geographical population had a different tag SNP selection and
haplotype distribution for CYP2E1. In addition, each geographical
population had one dominant haplotype with a frequency higher than
55%. The results show that there was a different haplotype structure
and haplotype distribution for each of the four geographical
populations.
Besides comparing the data for the populations from the four
different geographic areas, we also carried out a comparisonwith data
previously reported in other ethnic groups, such as other Asian,
European, American, and other Caucasian populations. As shown in
Table 6, the frequency of CYP2E1⁎1D allele in the Chinese Han
population (17%) is notably higher than in the Swedish population
(1.1%) but similar to the data for other Asian subjects. The frequencyTable 3
Fisher's P-value for SNPs in four different geographical Chinese Han populations.
SNP P-value
ST:SH ST:SY ST:XA SH:SY SH:XA SY:XA
−1653GNC 0.232560 0.271844 0.385953 0.018613 0.034225 0.808144
−1563TNA 0.557449 0.027629 0.013625 0.004161 0.001731 0.781501
−1513TNG 0.602211 0.019115 0.652966 0.065710 0.938842 0.053483
−1293GNC 0.345218 0.031257 0.024377 0.001937 0.001305 0.948816
−1053CNT 0.345218 0.144478 0.074654 0.015503 0.006030 0.745800
−1025TNC 0.428031 0.049478 0.060035 0.005500 0.007030 0.927007
−929ANG 0.399217 0.988577 0.235403 0.403202 0.038882 0.224739
−806TNC 0.678077 0.055619 0.033794 0.018957 0.010428 0.849288
−352ANG 0.214966 1.000000 0.446668 0.214966 0.046230 0.446668
−333TNA 0.794003 0.527118 0.460001 0.400394 0.343490 0.915438
227GNA 0.156279 – – 0.156279 0.156279 –
517GNA – – 0.316728 – 0.316728 0.316728
1263CNT 0.073565 0.891759 0.675370 0.054494 0.168717 0.579087
1523TNA 0.550197 0.287882 0.294961 0.626768 0.648495 0.966329
1528TNC 0.550197 0.287882 0.294961 0.626768 0.648495 0.966329
SH: Shanghai; ST: Shantou; SY: Shenyang; XA: Xian.of this allele is signiﬁcantly higher than in the data reported for
Europeans, Americans, and other Caucasians. As for CYP2E1⁎5, the
frequency of 16.1% is lower than that found in some Asian
populations, although slightly higher than in some others, and much
higher than among Europeans and Americans. In addition, the
frequency of the CYP2E1⁎7 allele in the Chinese Han population
(33.9%) is much higher than in the German (3.7%) and other European
populations (Table 6).
Discussion
CYP2E1, which makes up less than 1% of the total hepatic P450
isoforms, plays a very important part in the metabolism of drugs and
low molecular weight compounds. Polymorphisms among CYP450
isoforms are well known.4 In particular, several polymorphic sites of
CYP2E1 have been associated with genetic susceptibility to several
types of chemical-induced diseases, including several types of cancer
underlining the importance of analyzing such polymorphism in
individual populations. Few studies to date have focused on the
Chinese Han population. Our systematic polymorphism analysis of
CYP2E1 in different geographic Han populations of the Chinese
mainland and the comparison of the CYP2E1 polymorphisms with
those from other racial and ethnic groups should contribute
signiﬁcantly to a better understanding of the polymorphism patternTable 4
CYP2E1 genotypes in four different geographical Chinese populations.
CYP2E1 genotype Genotype frequency (%)
Shantou Shanghai Shenyang Xian Chinese
⁎1/⁎1 30.2 38.7 39.6 38.4 36.7
⁎1/⁎2 0 0 0 0 0
⁎1/⁎5 4.2 3.1 1 2.1 2.6
⁎1/⁎7 24 13.5 25 31.3 23.4
⁎2/⁎2 0 0 0 0 0
⁎2/⁎5 0 0 0 0 0
⁎2/⁎7 0 2 0 0 0.5
⁎5/⁎5 3.1 8.3 1 4.2 4.2
⁎5/⁎7 22.9 24 21.9 16.7 21.4
⁎7/⁎7 15.6 10.4 11.5 7.3 11.2
Total 100 100 100 100 100
Fig. 1. . Pairwise linkage disequilibrium of the SNPs in the CYP2E1 gene in the four geographical Chinese populations of (A) Shanghai, (B) Xian, (C) Shenyang, and (D) Shantou. An r2
color scheme is used to display LD with black for very strong LD (r2 =1), white for no LD (r2 =0), and shades of gray for intermediate LD (0br2b1).
227K. Tang et al. / Genomics 95 (2010) 224–229of CYP2E1 and of potential beneﬁts for personalized medicine in the
Chinese Han population.
One novel nonsense mutation, which could result in the change of
Arg to stop codon, was detected for the ﬁrst time in the Chinese
population. Further possible effects of this variant were evaluated on
the basis of CYP2E1 crystal structure. The nonsense mutation that
produces a reduced protein content of 336 amino acids could result inTable 5
The tag SNPs and haplotypes of the CYP2E1 gene in four different geographical Chinese
populations.
Region Tag SNPs Haplotypes⁎ Frequency
(%)





Shanghai g.-1053CNT; −1025TNC; −352ANG; CTATCTT 58.3
g.-333TNA; g.1263CNT; g.1523TNA; TCAACAC 23.8
g.1528TNC CTGATAC 9.3
CTGACAC 4.7
Shenyang g.-333TNA; g.1263CNT; ACTT 63.4
g.1523TNA; g.1528TNC TCAC 36.6
Xian g.-1513TNG; g.-1293GNC; g.-1053CNT; TGCTATATCTT 60.3




⁎ The haplotypes are those composed of the tag SNPs selected in each population.
Only haplotypes with a frequency greater than 3% are listed.a total loss of enzyme activity. It is known that the heme, which forms
several hydrogen bonds with the side chain of surrounding amino
acids, is located in the center of CYP2Es (Fig. 2). Thus, the mutation
that breaks the original protein structure causes obvious hindrance in
the formation of hydrogen bonds and could result in the almost
complete displacement of heme. We also found in the promoter
region six novel variants, which might change the efﬁciency of
transcription binding factor. They were identiﬁed through the
application of CONREAL, a tool that has been used widely to predict
this factor, and their effects on the expression of the CYP2E1 gene
need to be further investigated.
The identiﬁcation of the CYP2E1 alleles and genotypes was based
on the polymorphisms found in the present study. Four different
CYP2E1 alleles and 7 genotypes were detected. Some allele and
genotype frequencies demonstrated differences among the four
different geographic populations. These differences might be related
to the following factors: genetic background, cultural variants, and
other factors such as living environment and dietary habits. Fisher's P-
values for the four groups ranged from 0.0001 to 0.05, indicating
signiﬁcant differences among the four populations. However, the
frequencies of polymorphisms in Chinese mainland were consistent
with the Wang et al. report for Hans in Taiwan [35].
Linkage disequilibrium between each pair of SNPs was calculated
for each of the four populations using Haploview analysis. The results
not only suggested the existence of high levels of LD over some
genomic regions spanning the CYP2E1 gene but also showed a
different LD pattern for each population. The haplotypes were
constructed from the tag SNPs selected according to different LD
Table 6
Comparison of CYP2E1 allele frequencies with those in other ethnic groups.
Population n CYP2E1 allele (%) Reference
⁎1C ⁎1D ⁎5 ⁎7
Chinese 400 83 17 16.1 33.9 This report
Asians
Japanese 192 75.2 22.7 [16]
Indo-Asian 24 68.8 31.2 [17]
Taiwanese 210 79.8 20.2 [17]
Korean 172 20 [20]
Thai 231 15 [21]
Japanese 202 19.3 [22]
Non-Asians
Swedish 95 98.9 1.1 [7]
North American White 125 97.6 1.6 [16]
Americans 172 98 2 [17]
Canadian Native Indians 114 90.7 9.3 [17]
Caucasians 867 97.9 2.1 [17]
African American 102 86.6 13.4 [17]
African Canadian 29 89.7 10.3 [17]
Finnish 121 89.3 10.7 [18]
French 349 98.4 1.6 [19]
European Americans 126 1 [23]
African Americans 449 4 [23]
Italian 124 3.6 [24]
Finnish 121 1.2 [25]
Turkish 153 2 [26]
Australian Aborigines 239 2 [27]
Czech 416 2.3 [28]
Swiss 148 5 [29]
Northern European⁎ 115 5.2 [30]
German⁎ 299 3.7 [31]
Swedish⁎ 37 4.1 [32]
Turkish⁎ 206 6.8 [33]
British Caucasoids⁎ 155 5.2 [34]
⁎ The frequencies are calculated according to the data presented in the
corresponding articles.
228 K. Tang et al. / Genomics 95 (2010) 224–229structure, so each geographical population had its own haplotype
structure and haplotype distribution for CYP2E1. However, the
combined effects of some decreased function variants produce
inactive enzymes. Different polymorphisms and their combinations
may produce markedly different results in terms of CYP2E1 activity.Fig. 2. Shortened protein caused by nonsense mutation. One hundred ﬁfty-seven amino
acids (shown in red) of the protein disappear after nonsense mutation. The heme is
located in the center of the protein. Hydrogen bonds are represented as dashed lines.
The mutation site is shown in white.Tag SNP detection and haplotype analysis would therefore be helpful
in identifying the metabolizer phenotype.
CYP2E1 polymorphism frequencies show variability across differ-
ent races and ethnicities, as do most other xenobiotic-metabolizing
enzymes. We therefore compared the frequencies of alleles and
genotypes with those of other ethnic populations. As can be seen from
Table 6, the frequencies and alleles detected in our Han population are
similar to those in the Japanese and other Asian populations, although
some variants in these populations are not present in the Han Chinese.
However, the comparison with Europeans, Americans, and some
other Caucasians showed signiﬁcant differences. For instance, the
frequency of alleles ⁎5 is 1.2% in Finns, 1% in European Americans, and
4% in African Americans, compared with 16.1% in our study. Allele ⁎7
showed a high frequency, of 33.9%, in our population compared to
3.7% among German (3.7%). We found a much higher frequency of
alleles with a CYP2E1 duplication in our population (17%) compared
with Americans (2%). These results may indicate that environmental
characteristics, such as culture and national diet can affect the
polymorphisms of CYP2E1.
In conclusion, this is the ﬁrst large-scale systematic analysis of
polymorphisms across the whole CYP2E1 gene in the Chinese Han
population. We also conducted a function prediction, an LD pattern
analysis, and a tag SNP selection and haplotype analysis in four
different geographical Han populations in mainland China. These data
can serve as a baseline for larger studies on themechanism and effects
of CYP2E1 polymorphisms in Asian populations. It should also provide
important data for the advance of personalized medicine.Acknowledgments
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